



## Defense Health Agency (DHA) Clinical Communities Speaker Series

### Resource List – January 2020

#### Advances in Women's Health

##### Enhanced Recovery after Surgery (ERAS) in OB/GYN in the Era of the Opioid Epidemic

[Opioid Analgesia for Medical Abortion: A Randomized Controlled Trial](#) integrates technology to investigate the post-surgical pain experienced by patients who recently underwent a medical abortion. Results conclude that standard dosages of oxycodone do not decrease pain or improve satisfaction in the patients that were tested. Implications for managing the opioid crisis based on these outcomes is discussed.

[Ultrarestrictive opioid prescription protocol \(UROPP\)](#) implemented in 2017 through 2018 in post-operative gynecologic cancer patients for pain management is reviewed. The management of postsurgical pain is based on the dosage required during hospitalization. Methods and recommendations for tapering prior to discharge is discussed.

[Opioid Use in Pregnancy, Neonatal Abstinence Syndrome, and Childhood Outcomes: Executive Summary of a Joint Workshop by the Eunice Kennedy Shriver National Institute of Child Health and Human Development, American Congress of Obstetricians and Gynecologists, American Academy of Pediatrics, Society for Maternal-Fetal Medicine, Centers for Disease Control and Prevention and the March of Dimes Foundation](#) addressed the rise in neonatal abstinence syndrome and the research gaps related to this growing epidemic. Key scientific opportunities to advance an understanding of the impact of the opioid epidemic in this population is discussed.

[Medications to Treat Opioid Use Disorder During Pregnancy](#) is a fact sheet created by the Substance Abuse and Mental Health Services Administration (SAMHSA) to inform providers of post-surgical state of science treatment recommendations for prescribing opioids during pregnancy. Current research, impact of over prescribing on fetal development and education for the expectant mother are outlined for practitioner guidance and dissemination in patient care.

#### References

- Colwill, A.C., Bayer, L.L., Bednarek, P., Garg, B., Jensen, J.T., Edelman, A.B. (2019). Opioid analgesia for medical abortion: A randomized controlled trial. *Obstetrics and Gynecology*, 134(6), 1163-1170.  
<https://insights.ovid.com/crossref?an=00006250-201912000-00006>
- Mark, J., Argentieri, D.M., Guitierrez, C.A., Morrell, K., Eng, K., Hutson, A.D., Mayor, P., Szender, J.B., Starbuck, K., Lynam, S., Blum, B., Akers, S. Lele, S. Paragh, G., Odunsi, K., de Leon-Casasola, O., & Fredrick, P.J. (2018). Ultrarestrictive Opioid Prescription Protocol for Pain Management after



## **Defense Health Agency (DHA) Clinical Communities Speaker Series**

Gynecological and Abdominal Surgery. *Journal of the American Medical Association*, 1(8), e185452. <http://www.doi.10.1001/jamanetworkopen.2018.5452>

Reddy, U.M., Davis, J.M., Ren, Z., Greene, M.F. and the Opioid Use in Pregnancy, Neonatal Abstinence Syndrome, and Child Outcomes Workshop Invited Speakers. (2018). Opioid Use in Pregnancy, Neonatal Abstinence Syndrome, and Childhood Outcomes: Executive Summary of a Joint Workshop by the Eunice Kennedy Shriver National Institute of Child Health and Human Development, American Congress of Obstetricians and Gynecologists, American Academy of Pediatrics, Society for Maternal-Fetal Medicine, Centers for Disease Control and Prevention and the March of Dimes Foundation. *Obstetrics and Gynecology*, 130(1), 10-28.

<http://www.doi:10.1097/AOG.0000000000002054>

Substance Abuse and Mental Health Services Administration. (2017). Medication to Treat Opioid Use Disorder During Pregnancy. Information for Providers-FACT SHEET.

[https://store.samhsa.gov/system/files/pre\\_pregnancy\\_info\\_sheet\\_042219\\_508\\_0.pdf](https://store.samhsa.gov/system/files/pre_pregnancy_info_sheet_042219_508_0.pdf)